New hope for sarcoma patients: immunotherapy plus chemo shows promise
NCT ID NCT04589741
First seen Jun 17, 2026 · Last updated Jun 17, 2026
Summary
This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (CAV/IE) can help people with advanced bone or soft tissue sarcoma that has not responded to previous treatments. About 134 participants will be randomly assigned to receive either the combination or chemotherapy alone. The goal is to see if the combination slows tumor growth and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.